Cargando…

A New Monoclonal Antibody Demonstrates That Muc4, the Intramembrane Ligand for Erbb2/Her2/Neu, Is Overexpressed in Multiple Carcinomas

Detalles Bibliográficos
Autores principales:	Zhang, Jin, Carraway, Kermit L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	TheScientificWorldJOURNAL 2002
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6009234/ https://www.ncbi.nlm.nih.gov/pubmed/29973843 http://dx.doi.org/10.1100/tsw.2002.66

Ejemplares similares

Muc4\sialomucin Complex, A Specific Intramembrane Modulator of ERBB2/HER2/NEU, Potentiates Primary Tumor Growth and Suppresses Apoptosis in A Xenotransplanted Melanoma
por: Carraway, Coralie Carothers, et al.
Publicado: (2001)

cERBB-2/Her-2 Neu Overexpression and Prognostic Significance in Uterine Carcinosarcoma
por: Semiz, Huseyin Salih, et al.
Publicado: (2023)

Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tumours.
por: DiGiovanna, M. P., et al.
Publicado: (1996)

Evaluation of C-ErbB-2 Overexpression and Her-2/neu Gene Copy Number Heterogeneity in Barrett’s Adenocarcinoma
por: Walch, Axel, et al.
Publicado: (2000)

ErbB2/HER2/Neu resembles an autoinhibited invertebrate EGF receptor
por: Alvarado, Diego, et al.
Publicado: (2009)

Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
por: Tokuda, Y, et al.
Publicado: (1999)

Anti-Her-2/neu antibody induces apoptosis in Her-2/neu overexpressing breast cancer cells independently from p53 status
por: Brodowicz, T, et al.
Publicado: (2001)

Conformational changes in receptor tyrosine kinase signaling: an ErbB garden of delights
por: Carraway, Kermit L, et al.
Publicado: (2009)

HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma
por: Plum, Patrick Sven, et al.
Publicado: (2019)

Small Molecule Tyrosine Kinase Inhibitors of ErbB2/HER2/Neu in the Treatment of Aggressive Breast Cancer
por: Schroeder, Richard L., et al.
Publicado: (2014)

LMO4 is an essential mediator of ErbB2/HER2/Neu-induced breast cancer cell cycle progression
por: Montañez-Wiscovich, ME, et al.
Publicado: (2009)

Breast Cancer and Her-2/Neu
por: Sherwood, Roy
Publicado: (2005)

HER2/neu overexpression in the development of muscle-invasive transitional cell carcinoma of the bladder
por: Latif, Z, et al.
Publicado: (2003)

TOPOIIα and HER-2/neu overexpression/amplification in Barrett’s oesophagus, dysplasia and adenocarcinoma
por: Rossi, Elisa, et al.
Publicado: (2010)

A monoclonal antibody targeting ErbB2 domain III inhibits ErbB2 signaling and suppresses the growth of ErbB2-overexpressing breast tumors
por: Meng, Y, et al.
Publicado: (2016)

Expression of oncogenes in thyroid tumours: coexpression of c-erbB2/neu and c-erbB.
por: Aasland, R., et al.
Publicado: (1988)

Prognostic Value of KIF2A and HER2-Neu Overexpression in Patients With Epithelial Ovarian Cancer
por: Wang, Di, et al.
Publicado: (2016)

Activation of the Her2/neu receptor leads to antiestrogen resistance, but acquired resistance is not caused by altered ErbB expression and activation
por: Larsen, SS, et al.
Publicado: (2000)

HER-2/neu diagnostics in breast cancer
por: Carney, Walter P, et al.
Publicado: (2007)

The Clinical Importance of the Heterogeneity of HER2 neu
por: Davila, Enrique, et al.
Publicado: (2010)

Retargeting of NK-92 Cells against High-Risk Rhabdomyosarcomas by Means of an ERBB2 (HER2/Neu)-Specific Chimeric Antigen Receptor
por: Gossel, Leonie D. H., et al.
Publicado: (2021)

Adjuvant effect of HER-2/neu-specific adenoviral vector stimulating CD8(+) T and natural killer cell responses on anti-HER-2/neu antibody therapy for well-established breast tumors in HER-2/neu transgenic mice
por: Chen, Y, et al.
Publicado: (2011)

Clinical significance of Akt and HER2/neu overexpression in African-American and Latina women with breast cancer
por: Wu, Yanyuan, et al.
Publicado: (2008)

LED-FISH: Fluorescence microscopy based on light emitting diodes for the molecular analysis of Her-2/neu oncogene amplification
por: Lang, Dagmar S, et al.
Publicado: (2008)

HER 2/neu protein expression in colorectal cancer
por: Schuell, B, et al.
Publicado: (2006)

HER-2/neu Testing and Therapy in Gastroesophageal Adenocarcinoma
por: Moelans, Cathy B., et al.
Publicado: (2010)

Anti-HER2/Neu passive-aggressive immunotherapy
por: Mortenson, Eric D, et al.
Publicado: (2014)

HER2/neu testing in primary colorectal carcinoma
por: Ingold Heppner, B, et al.
Publicado: (2014)

Review of the Role of HER2/neu in Colorectal Carcinomas
por: Achalla, Lakshmi Sai Vijay, et al.
Publicado: (2022)

Expression of Septin 2 and Her2/neu in Colorectal Cancer
por: Hanbuli, Hala M. El, et al.
Publicado: (2021)

Structural basis for the oncogenic signalling complex formed by Grb2 and Gab2 in Her2 (ErbB2/Neu)-driven breast cancers and CML cells
por: Tsirka, T, et al.
Publicado: (2009)

Effects of ErbB2 Overexpression on the Proteome and ErbB Ligand-specific Phosphosignaling in Mammary Luminal Epithelial Cells
por: Worthington, Jenny, et al.
Publicado: (2017)

Conjugation of Monoclonal Antibodies to Super Paramagnetic Iron Oxide Nanoparticles for Detection of her2/neu Antigen on Breast Cancer Cell Lines
por: Shamsipour, Fereshteh, et al.
Publicado: (2009)

Monoclonal antibodies reacting with the MUC2 mucin core protein.
por: Devine, P. L., et al.
Publicado: (1993)

Societal Costs and Benefits of Treatment with Trastuzumab in Patients with Early HER2neu-Overexpressing Breast Cancer in Singapore
por: de Lima Lopes, Gilberto
Publicado: (2011)

Overexpression of miR-489 derails mammary hierarchy structure and inhibits HER2/neu-induced tumorigenesis
por: Patel, Y, et al.
Publicado: (2018)

Antibody–Drug Conjugates (ADC) in HER2/neu-Positive Gynecologic Tumors
por: McNamara, Blair, et al.
Publicado: (2023)

Inhibition of Cell Growth and Induction of Apoptosis by Antrodia camphorata in HER-2/neu-Overexpressing Breast Cancer Cells through the Induction of ROS, Depletion of HER-2/neu, and Disruption of the PI3K/Akt Signaling Pathway
por: Lee, Chuan-Chen, et al.
Publicado: (2012)

Study of the Relationship between MMP-2 and MMP-9 and Her2/neu Overexpression in Gastric Cancer: Clinico-Pathological Correlations
por: Jafari, Elham, et al.
Publicado: (2021)

Long-term remission of a Her2/neu positive primary breast cancer under double monoclonal antibody therapy with trastuzumab and bevacizumab
por: Königsberg, Robert, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_tnd5b37ag1jqths3d26hblb4bv